Core Viewpoint - The recent draft of the "Securities Company Classification Evaluation Regulations" aims to shift the focus of the industry from "scale competition" to "quality competition," promoting differentiated development paths for small and medium-sized institutions [1][2] Group 1: Industry Role and Function - Securities firms play a crucial role in China's capital market and financial system, facilitating a healthy investment and financing cycle, serving the real economy, national strategies, and wealth management for residents [1] - The classification results show a stable number of firms across categories, with A, B, and C class companies accounting for 50%, 40%, and 10% respectively, and approximately 14 firms maintaining an AA rating [1] Group 2: Regulatory Changes and Focus - The revised regulations emphasize guiding securities firms to enhance their functional roles and professional capabilities, with a new evaluation framework focusing on risk management, compliance, business development, and functional performance [2] - A new "functional performance" evaluation organized by the China Securities Association will be incorporated into the classification evaluation to better assess firms' contributions [2] Group 3: Business Development and Performance Metrics - The regulations remove the revenue-based scoring system and increase the emphasis on net asset return, raising the maximum score from 1 to 2 points, encouraging firms to focus on efficiency and quality rather than just scale [4][5] - The projected net asset return for the securities industry in 2024 is 5.5%, a 0.7 percentage point increase year-on-year, with firms like Dongfang Caifu leading at 12.6% [4] Group 4: Differentiated Development for Small and Medium-sized Firms - The regulations expand the scoring criteria for net asset return and major business income from the top 20 to the top 30 firms, allowing smaller firms to explore differentiated development paths [5] - Small and medium-sized firms are encouraged to focus on high-end wealth management and specific industry sectors to create specialized advantages and provide tailored financing solutions [5][6] Group 5: Encouragement of Long-term Investment - The regulations also introduce new indicators to promote long-term capital inflow, including metrics for self-investment in equity assets and management of equity fund products, encouraging firms to enhance their contributions to long-term wealth management [6]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals provided misleading information regarding the safety and clinical trial protocol of RP-A501, particularly concerning serious adverse events, including participant deaths [3][4]. - On May 27, 2025, the U.S. FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a serious adverse event, which was not disclosed to investors prior to the protocol amendment [4]. Group 2: Lead Plaintiff Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [5]. - The lead plaintiff is typically the investor with the greatest financial interest in the case and can select a law firm to litigate the lawsuit [5]. Group 3: Company Background - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare diseases [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

哈梅内伊高级顾问：即便核设施被摧毁 游戏也远未结束 智通财经6月23日电，据央视新闻，伊朗最高领袖哈梅内伊的高级顾问阿里·沙姆哈尼当地时间22日傍晚 在社交媒体上发文称，即使伊朗核设施被摧毁，游戏也远未结束。浓缩（铀）材料、知识储备和政治意 志依然存在。"凭借正当防卫权，善于谋略、避免盲目打击的一方将掌握政治与行动主动权。好戏还在 后头！"6月13日，沙姆哈尼在以军对伊朗的袭击中受重伤，此后有媒体报道称其已于14日死亡。6月21 日，沙姆哈尼本人在社交媒体上发文否认身亡传闻。 ...

Core Insights - The global obesity drug market is projected to exceed $100 billion by 2030, driven by the increasing number of obese individuals worldwide [1][2] - Major pharmaceutical companies, both multinational and domestic, are intensifying their efforts in the obesity drug sector, leading to fierce competition in technology, capital, and market presence [2] Domestic Drug Development - Domestic companies are making significant progress in the development of obesity drugs, with recent approvals for clinical trials of GLP-1 class innovative drugs by Changshan Biochemical Pharmaceutical and Guangdong Zhongsheng Pharmaceutical [3] - Changshan Biochemical has received approval for clinical trials of its injection for weight loss, while Guangdong Zhongsheng has completed the first participant enrollment for its innovative peptide drug RAY1225 in a Phase III trial [3] - The global sales of GLP-1 receptor agonists (GLP-1RA) are expected to exceed $150 billion by 2031, indicating a strong market potential [3] Market Dynamics - The global obesity drug market is currently dominated by Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, with semaglutide projected to generate sales of 6.6 billion yuan in China by 2024 [4] - The domestic GLP-1 drug market is expected to surpass 20 billion yuan by 2030, with several domestic GLP-1 drugs already approved [5] - The influx of domestic companies into the obesity drug market reflects a consensus on the explosive growth potential of the sector, although it may lead to intensified price competition [5] Competitive Landscape - Chinese pharmaceutical companies are leveraging multi-target innovation and differentiated development strategies to gain a competitive edge in the GLP-1 market [6] - Jiangsu Hengrui Medicine's dual-target drug HRS9531 has shown superior weight loss results compared to existing treatments, indicating the potential for domestic products to compete internationally [6] - Cross-border collaborations in the GLP-1 field are increasing, with companies like Federated Pharmaceutical and Hansoh Pharmaceutical engaging in licensing agreements to expand their market reach [6][7] Future Outlook - The obesity drug market is expected to undergo a significant reshuffle in the next 3 to 5 years, with products that demonstrate clinical value and technological barriers likely to prevail [7]

本报记者 袁传玺 近日，国际数据公司IDC发布的《中国2024年AI数字人市场份额》报告显示，2024年中国AI数字人市场规模约41.2亿元， 同比增长85.3%，实现高速增长。 国内AI数字人市场的高速增长，离不开技术的进步。在生成式AI与大模型技术浪潮下，2025年，AI数字人正以前所未有的 速度从概念走向规模化应用，成为产业数字化转型进程中的焦点与新引擎。 百度集团股份有限公司（以下简称"百度"）副总裁、电商总经理平晓黎表示，今年4月份百度发布的高说服力数字人已让 数字人进入3.0时代，标志着智能电商迈入新篇章，新一代高说服力数字人成为了一个"形神音容"高度协调、会思考决策、能协 作完成特定任务的超级智能体。 AI数字人加速普及 以百度高说服力数字人为例，百度研制的多模协同的数字人技术，基于文心4.5T实现了融合多模规划与深度思考的剧本生 成，由剧本驱动数字人多模协同，实现动态决策的实时交互，使数字人的"神、形、音、容、话"达到高度统一，最终呈现出一 个具备高表现力、内容吸引人、"人—物—场"可自由交互的超拟真数字人。 平晓黎表示，百度的罗永浩数字人已达到媲美头部主播的体感效果，随着大模型与多模能力发展 ...

Core Insights - The release of the "Listed Companies Data Value Research Ranking" provides a new perspective on the data assetization process of listed companies in China [1][2] - The ranking identifies leading companies in data assetization and highlights the challenges they face, serving as a reference for other companies [1][4] Group 1: Ranking and Performance - The ranking includes two categories: the top 100 listed companies with data resources included in their financial statements and the top 100 without [1] - The number of companies reporting data assets increased from 17 to 100, with the disclosed scale rising from 0.79 billion to 21.64 billion [2] - The top three companies in the ranking are: - Toprays Technology Co., Ltd. with a score of 95.86 - Shanghai Hehe Information Technology Co., Ltd. with 95.63 - Meiri Interactive Co., Ltd. with 94.73 [2] Group 2: Industry Insights - The software and information technology services industry emerged as a significant winner, with five companies in the top ten [3] - Major telecommunications companies such as China Mobile, China Unicom, and China Telecom ranked seventh to ninth, respectively [3] - The ranking also evaluated 100 companies that have not yet included data assets in their financial statements, providing a comprehensive view of the market's data assetization progress [3] Group 3: Challenges and Recommendations - Companies face challenges in data assetization, including unclear property rights and the distinction between public and commercial data [5] - Recommendations for companies include precise positioning within the industry chain, understanding data application scenarios, and developing suitable digital transformation strategies [6] - Emphasis on the importance of data governance and compliance with legal regulations to maximize data value [6][7]

Group 1 - The article discusses the author's journey into investing, starting in high school in 2011, focusing on REITs, preferred stocks, and high-yield bonds, indicating a long-standing interest in markets and the economy [1] - The author has recently adopted a strategy that combines long stock positions with covered calls and cash secured puts, emphasizing a fundamental long-term investment approach [1] - The author primarily covers REITs and financials on Seeking Alpha, with occasional articles on ETFs and other stocks influenced by macro trade ideas [1]

6月20日，深圳市龙岗区坪地街道举办2025年"校企联谊"人才培养引进合作交流活动，以深化辖区企业与全国各地院校的长期合作机制，为经济高质量发展 提供人才支撑。活动邀请了湖南理工学院、大连工业大学等13家院校代表，深圳市建滔科技有限公司、深圳市杰科数码有限公司等24家坪地重点企业参加。 下午的座谈会上，街道党工委副书记、人大工委主任薛荣喜介绍了坪地街道概况及产业发展中对实用型技能人才的迫切需求。坪地街道始终致力于为人才营 造优质的生活与发展环境，助力企业扎根坪地、发展壮大。此次"校企联谊"活动旨在畅通人才供需两端，拓宽人才共育共引通道，通过加强校企合作交流， 为辖区企业高效精准输送高素质技术技能人才，为院校毕业生搭建优质就业创业平台，最终实现校、企、地三方发展共赢。 在随后的自由洽谈环节，校企双方围绕人才培养、技术合作、产学研一体化等议题展开了深入交流讨论。双方展现出强烈的合作意向，明确了彼此需求与合 作方向。现场交流气氛活跃，双方互加微信、积极对接，现场共签订合作协议24份。此外，部分院校代表还热情邀请坪地企业赴校开展招聘宣讲等活动。 龙岗区人力资源服务中心副主任张伟球详细介绍了龙岗区的经济发展概况、创新活 ...

花山岩画是战国至东汉时期生活在左江流域的壮族先民所作，主要分布在广西崇左市境内的宁明、龙州、江州、扶绥、大新五个县区内，距今有 两千多年的历史，2016年被列入《世界遗产名录》。 宁明县位于广西西南边陲，现存有多处岩画，其中一处是左江流域面积最大的单体涂绘类岩画，面积约8000多平方米，可辨识图像约1900多个， 涉及正身人像、侧身人像、铜鼓图像、渡船图像等，具有极高的艺术价值和文化价值。 历经两千余年的风雨侵蚀等自然力的破坏，部分岩画不可避免地出现了风化溶蚀，有的甚至已从岩体脱落。1984年，宁明县成立文物管理所，此 后持续对岩画实施保护管理。2015年5月，花山岩画历时5年完成了岩画本体抢救性修复保护工程，出现风化、开裂等问题的岩画均得到有效加固 和修复。 此外，当地不断完善岩画监测预警体系建设，强化对花山岩画本体及周边环境的监测、监控和预警，建立花山岩画保护监测站，不间断值班和定 期巡查成为日常。通过运用高科技手段，将花山岩画的影像数字化，实现了岩体裂隙、温度、湿度等监测数据实时与国家文物局数据监测平台无 缝连接，确保了岩画的安全保存。目前，花山岩画已开展16个保护工程项目和课题研究项目。 6月19日， ...

智通财经6月23日电，据央视新闻，据叙利亚媒体22日报道，叙首都大马士革东部一座教堂当天发生爆 炸，已造成25人丧生，数十人受伤。 叙利亚首都大马士革一座教堂发生爆炸25人丧生 ...